journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/28060374/heterogeneous-expression-of-the-collagen-receptor-ddr1-in-chronic-lymphocytic-leukaemia-and-correlation-with-progression
#1
G Barisione, M Fabbi, G Cutrona, L De Cecco, S Zupo, B Leitinger, M Gentile, M Manzoni, A Neri, F Morabito, M Ferrarini, S Ferrini
No abstract text is available yet for this article.
January 6, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/27983727/the-complexity-of-interpreting-genomic-data-in-patients-with-acute-myeloid-leukemia
#2
A Nazha, A Zarzour, K Al-Issa, T Radivoyevitch, H E Carraway, C M Hirsch, B Przychodzen, B J Patel, M Clemente, S R Sanikommu, M Kalaycio, J P Maciejewski, M A Sekeres
Acute myeloid leukemia (AML) is a heterogeneous neoplasm characterized by the accumulation of complex genetic alterations responsible for the initiation and progression of the disease. Translating genomic information into clinical practice remained challenging with conflicting results regarding the impact of certain mutations on disease phenotype and overall survival (OS) especially when clinical variables are controlled for when interpreting the result. We sequenced the coding region for 62 genes in 468 patients with secondary AML (sAML) and primary AML (pAML)...
December 16, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27983726/risk-stratification-in-myeloma-by-detection-of-circulating-plasma-cells-prior-to-autologous-stem-cell-transplantation-in-the-novel-agent-era
#3
R Chakraborty, E Muchtar, S K Kumar, D Jevremovic, F K Buadi, D Dingli, A Dispenzieri, S R Hayman, W J Hogan, P Kapoor, M Q Lacy, N Leung, M A Gertz
The impact of circulating plasma cells (CPCs) prior to autologous stem cell transplantation (ASCT) for multiple myeloma has not been defined in the novel agent era. We evaluated the impact of pre-transplant CPCs, detected by six-color flow cytometry in patients undergoing early ASCT on post-transplant response, progression-free survival (PFS) and overall survival (OS). CPCs were detected in 162 out of 840 (19.3%) patients, with the median number of CPCs being 58 per 150 000 events. Ninety-nine percent of patients had received proteasome inhibitor and/or immunomodulator-based induction...
December 16, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27983725/a-gene-expression-inflammatory-signature-specifically-predicts-multiple-myeloma-evolution-and-patients-survival
#4
C Botta, M T Di Martino, D Ciliberto, M Cucè, P Correale, M Rossi, P Tagliaferri, P Tassone
Multiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis, bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine pathways as the most progressively affected during disease evolution...
December 16, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935581/comprehensive-study-on-erg-gene-expression-in-normal-karyotype-acute-myeloid-leukemia-erg-expression-is-of-limited-prognostic-value-whereas-the-accumulation-of-adverse-prognostic-markers-stepwise-worsens-the-prognosis
#5
https://www.readbyqxmd.com/read/27935580/second-malignancies-in-the-context-of-lenalidomide-treatment-an-analysis-of-2732-myeloma-patients-enrolled-to-the-myeloma-xi-trial
#6
J R Jones, D A Cairns, W M Gregory, C Collett, C Pawlyn, R Sigsworth, A Striha, R Henderson, M F Kaiser, M Jenner, G Cook, N H Russell, C Williams, G Pratt, B Kishore, J Lindsay, M T Drayson, F E Davies, K D Boyd, R G Owen, G H Jackson, G J Morgan
We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95% confidence interval (CI) 0.4-1.0%), 2.3% (95% CI 1.6-2.7%) and 3.8% (95% CI 2.9-4.6%) at 1, 2 and 3 years, respectively. Patients receiving maintenance lenalidomide had a significantly higher SPM incidence overall (P=0...
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935579/mir-139-5p-is-a-potent-tumor-suppressor-in-adult-acute-myeloid-leukemia
#7
K Krowiorz, J Ruschmann, C Lai, M Ngom, T Maetzig, V Martins, A Scheffold, E Schneider, N Pochert, C Miller, L Palmqvist, A Staffas, M Mulaw, S R Bohl, C Buske, M Heuser, J Kraus, K O'Neill, C L Hansen, O I Petriv, H Kestler, H Döhner, L Bullinger, K Döhner, R K Humphries, A Rouhi, F Kuchenbauer
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935578/comment-on-blinatumomab-vs-historical-standard-therapy-of-adult-relapsed-refractory-acute-lymphoblastic-leukemia
#8
W H Tong
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935577/bone-marrow-fibrosis-grade-is-an-independent-risk-factor-for-overall-survival-in-patients-with-primary-myelofibrosis
#9
B Li, P Zhang, G Feng, Z Xu, T Qin, Y Zhang, Z Sha, D Dong, H Zhang, L Fang, L Pan, N Hu, S Qu, W Cai, G Huang, Z Xiao
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935576/acute-lymphoblastic-leukemia-relapsing-after-first-line-pediatric-inspired-therapy-a-retrospective-graall-study
#10
A Desjonquères, P Chevallier, X Thomas, F Huguet, T Leguay, M Bernard, J-O Bay, E Tavernier, A Charbonnier, F Isnard, M Hunault, P Turlure, M Renaud, J-N Bastié, C Himberlin, S Lepretre, B Lioure, V Lhéritier, V Asnafi, K Beldjord, M Lafage-Pochitaloff, M C Béné, N Ifrah, H Dombret
The outcome of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) relapsing after pediatric-inspired front-line therapy is ill known. Here 229 relapsing Ph- ALL younger adults (18-63 years) treated within the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/-2005 trials were considered. Salvage regimens consisted of potentially curative therapies in 194 cases, low-intensity therapies in 21, allogeneic stem cell transplant (allo-SCT) in 6 and best supportive care in 8...
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27911437/the-role-of-the-proteasome-in-aml
#11
REVIEW
C M Csizmar, D-H Kim, Z Sachs
Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML...
December 2, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27911436/uncovering-molecular-abnormalities-leading-to-the-warburg-effect-in-primary-refractory-diffuse-large-b-cell-lymphoma
#12
M Soleja, M Mims, G Rivero
No abstract text is available yet for this article.
December 2, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27858932/plasma-immunoprofiling-of-patients-with-high-risk-diffuse-large-b-cell-lymphoma-a-nordic-lymphoma-group-study
#13
F Pauly, K Fjordén, S Leppä, H Holte, M Björkholm, Ø Fluge, L Møller Pedersen, M Eriksson, A Isinger-Ekstrand, C A K Borrebaeck, M Jerkeman, C Wingren
No abstract text is available yet for this article.
November 18, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834943/idelalisib-improves-cd37-antibody-bi-836826-cytotoxicity-against-chemo-resistant-relapse-initiating-cll-cells-a-rationale-for-combination-treatment
#14
S Betrian, L Ysebaert, K H Heider, J P Delord, J J Fournié, A Quillet-Mary
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834942/measurement-of-%C3%AE-isomerized-c-terminal-telopeptide-of-type-i-collagen-in-patients-with-poems-syndrome-diagnostic-prognostic-and-follow-up-utilities
#15
X Huang, C Zhang, C Wang, Q Cai, X Cao, H Cai, L Zhang, J Feng, D Zhou, J Li
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834941/in-vivo-magnetic-resonance-imaging-of-a-mouse-model-of-myelofibrosis
#16
S Matsuura, S Patterson, H Lucero, O Leiva, A K Grant, V L M Herrera, K Ravid
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834940/high-prevalence-of-viral-hepatitis-in-a-series-of-splenic-marginal-zone-lymphomas-from-romania
#17
B Fetica, B Pop, M L Blaga, A Fulop, D Dima, M T Zdrenghea, C I Vlad, A S Bojan, P Achimas-Cadariu, C I Lisencu, A Irimie, D D Weisenburger
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834939/kinase-associated-gene-mutation-pattern-and-clinical-relevance-in-205-patients-with-core-binding-factor-leukemias
#18
Y-S Chen, P-P Wang, Y Hu, Y-M Zhu, B Chen, J-Y Huang, J-M Li, X-Q Weng, Y Yu, Y Shen
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834938/overexpression-of-rankl-by-invariant-nkt-cells-enriched-in-the-bone-marrow-of-patients-with-multiple-myeloma
#19
E Spanoudakis, M Papoutselis, E Terpos, M A Dimopoulos, C Tsatalas, D Margaritis, A Rahemtulla, I Kotsianidis, A Karadimitris
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834937/improved-survival-for-patients-diagnosed-with-chronic-lymphocytic-leukemia-in-the-era-of-chemo-immunotherapy-a-danish-population-based-study-of-10455-patients
#20
C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim, C U Niemann
The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3...
November 11, 2016: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"